Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
Alessandra D’Abramo, Serena Vita, Gaetano Maffongelli, Andrea Mariano, Chiara Agrati, Concetta Castilletti, Delia Goletti, Giuseppe Ippolito, Emanuele Nicastri
Abstract
Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19). The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins are reported.
Topics & Concepts
MedicineMonoclonal antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CD20Coronavirus disease 2019 (COVID-19)DrugImmune systemCoronavirusAntibodyImmunologyMonoclonalVirology2019-20 coronavirus outbreakDiseaseInternal medicinePharmacologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19